The Future of Toxicology Is Changing
- FDA is actively supporting New Approach Methodologies (NAMs)
- Movement toward reducing animal testing requirements
- Increased emphasis on human-relevant data models
What’s Driving the Change
PILLARS:
Regulatory Momentum
- FDA guidance and announcements encouraging alternatives
Scientific Advancement
- Organoids, in vitro systems, computational models
Speed & Cost Pressure
- Faster IND-enabling timelines
Ethical Expectations
- Reduction in animal use
But Here’s Where Problems Break Down
- “What alternatives are actually acceptable to the FDA?”
- “How do we validate non-animal data?”
- “When should we engage the FDA?”
- “How do we integrate NAMs into existing programs?”
- “What belongs in a briefing package?”
What the FDA Actually Expects
Justify Your Approach
- Scientific rationale for NAMs
- Relevance to human biology
Demonstrate Reliability
- Validation strategy
- Fit-for-purpose data
Engage Early
- INTERACT / Pre-IND
- Clear briefing materials
From Uncertainty to a Defensible Strategy – How Syner-G Can Help
- Evaluate your current toxicology program
- Identify where NAMs can be integrated
- Develop regulatory strategy + justification
- Write FDA-ready briefing packages
- Facilitate FDA interactions and meetings
As regulatory expectations evolve, toxicology programs must do more than reduce animal use. They must demonstrate scientific rigor, regulatory alignment, and a clear path to decision-making. With the right strategy, companies can reduce reliance on animal studies, strengthen regulatory confidence, and accelerate development timelines.
If you are evaluating how to evolve your toxicology approach or integrate new methodologies into your program, Syner-G can help you navigate the path forward with an informed, data-driven approach.
